You are here

Clinical Trials: Cord Blood

Comment

Discuss
Body: Condition:   Hematologic Malignancies
Interventions:   Biological: ProHema-CB;   Biological: Untreated CB
Sponsor:   Fate Therapeutics
Terminated - verified June 2017
Body: Conditions:   Degenerative Osteoarthritis;   Defect of Articular Cartilage
Interventions:   Biological: CARTISTEM;   Procedure: Microfracture
Sponsors:   Medipost Co Ltd.;   Dong-A Pharmaceutical Co., Ltd.
Completed - verified April 2017
Body: Condition:   Hematologic Malignancies
Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Drug: Thymoglobulin;   Radiation: Total Body Irradiation;   Biological: Umbilical Cord Blood
Sponsor:   University of Virginia
Terminated
Body: Condition:   Sickle Cell Disease & Thalassemia
Intervention:   Drug: NiCord
Sponsor:   Gamida Cell ltd
Recruiting - verified May 2017
Body: Conditions:   Leukemia;   Lymphoma
Interventions:   Drug: Rituximab;   Drug: 111In Ibritumomab;   Procedure: Planar Scintigraphy Imaging;   Drug: 90Y IbritumomabTiuxetan;   Drug: Fludarabine;   Drug: Bendamustine;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Mycophenolate;   Drug: G-CSF;   Procedure: Stem Cell Transplantation
Sponsors:   M.D. Anderson Cancer Center;   Spectrum Pharmaceuticals, Inc
Active, not recruiting - verified April 2017
Body: Conditions:   Blood And Marrow Transplantation;   Leukemia;   Lymphoma;   Transplantation Infection;   Transplantation, Bone Marrow
Interventions:   Drug: Melphalan;   Drug: Fludarabine;   Drug: Mycophenolate mofetil;   Drug: Tacrolimus;   Procedure: Cord Blood Infusion;   Drug: Rituximab;   Drug: ATG;   Drug: Busulfan;   Drug: Clofarabine;   Radiation: Total Body Irradiation (TBI)
Sponsors:   M.D. Anderson Cancer Center;   American Stem Cell, Inc.;   National Cancer Institute (NCI)
Completed - verified April 2017
Body: Condition:   Chronic Lymphocytic Leukemia
Intervention:   Drug: Allogeneic Cell Therapy w/ Tumor-derived Lypho
Sponsor:   National Cancer Institute (NCI)
Completed - verified April 24, 2013
Body: Condition:   Chronic Graft-versus-host Disease
Intervention:   Drug: Interleukin-2
Sponsors:   Dana-Farber Cancer Institute;   National Cancer Institute (NCI);   Prometheus Laboratories
Active, not recruiting
Body: Conditions:   Leukemia;   Lymphoma
Interventions:   Genetic: T-Cell Infusion;   Procedure: Cord Blood Infusion
Sponsor:   M.D. Anderson Cancer Center
Active, not recruiting - verified July 2017
Body: Condition:   Sickle Cell Disease
Interventions:   Drug: Fludarabine monophosphate;   Drug: Rituximab;   Drug: Busulfan;   Drug: ATG;   Drug: Cyclophosphamide;   Drug: Mycophenolate mofetil;   Drug: Tacrolimus
Sponsor:   Nationwide Children's Hospital
Terminated - verified July 2017
Body: Condition:   Myeloid Hematological Malignancies
Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Cord Blood Stem Cell Infusion
Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   Center for Cell and Gene Therapy, Baylor College of Medicine
Recruiting - verified September 2017
Body: Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin's Lymphoma;   Hodgkin's Disease
Intervention:   Drug: NiCord®
Sponsor:   Gamida Cell ltd
Completed
Body: Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Chronic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes
Interventions:   Procedure: umbilical cord blood transplantation;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Procedure: ex vivo-expanded cord blood progenitor cell infusion;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
Sponsors:   Fred Hutchinson Cancer Research Center;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
Completed - verified April 2017
Body: Conditions:   Cartilage Injury;   Osteoarthritis
Interventions:   Biological: Cartistem;   Procedure: Microfracture treatment
Sponsor:   Medipost Co Ltd.
Completed - verified April 2012
Body: Condition:   Epidermolysis Bullosa
Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Anti-thymocyte globulin;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Procedure: Mesenchymal stem cell transplantation;   Radiation: Total body irradiation;   Procedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantation
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified June 2017

Pages